Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)

MLA

Frédérique Penault-Llorca, et al. “Decision of Adjuvant Chemotherapy in Intermediate Risk Luminal Breast Cancer Patients: A Prospective Multicenter Trial Assessing the Clinical and Psychological Impact of EndoPredict® (EpClin) Use (UCBG 2–14).” Breast, vol. 49, no. 132–140, Feb. 2020, pp. 132–40. EBSCOhost, https://doi.org/10.1016/j.breast.2019.10.013.

APA

Frédérique Penault-Llorca, Fabrice Kwiatkowski, Antoine Arnaud, Christelle Levy, Marianne Leheurteur, Lionel Uwer, Olfa Derbel, Annick Le Rol, Jean-Philippe Jacquin, Christelle Jouannaud, Nathalie Quenel-Tueux, Véronique Girre, Cyril Foa, Emmanuel Guardiola, Alain Lortholary, Stéphanie Catala, Séverine Guiu, Alexander Valent, Diane Boinon, … Suzette Delaloge. (2020). Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14). Breast, 49(132–140), 132–140. https://doi.org/10.1016/j.breast.2019.10.013

Chicago

Frédérique Penault-Llorca, Fabrice Kwiatkowski, Antoine Arnaud, Christelle Levy, Marianne Leheurteur, Lionel Uwer, Olfa Derbel, et al. 2020. “Decision of Adjuvant Chemotherapy in Intermediate Risk Luminal Breast Cancer Patients: A Prospective Multicenter Trial Assessing the Clinical and Psychological Impact of EndoPredict® (EpClin) Use (UCBG 2–14).” Breast 49 (132–140): 132–40. doi:10.1016/j.breast.2019.10.013.